| scholarly article | Q13442814 |
| P2093 | author name string | Ebbing Lautenbach | |
| Warren B Bilker | |||
| Paul H Edelstein | |||
| Jennifer H Han | |||
| Kara B Mascitti | |||
| P2860 | cites work | Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia | Q28145964 |
| NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007 | Q28298371 | ||
| Invasive methicillin-resistant Staphylococcus aureus infections in the United States | Q29616087 | ||
| Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data | Q31011382 | ||
| Comparison of both clinical features and mortality risk associated with bacteremia due to community-acquired methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus | Q33378604 | ||
| Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in Taiwan: mortality analyses and the impact of vancomycin, MIC = 2 mg/L, by the broth microdilution method | Q33596888 | ||
| Risk factors for fluconazole-resistant Candida glabrata bloodstream infections | Q33932340 | ||
| Underestimation of vancomycin and teicoplanin MICs by broth microdilution leads to underdetection of glycopeptide-intermediate isolates of Staphylococcus aureus. | Q34108614 | ||
| Fitness cost of SCCmec and methicillin resistance levels in Staphylococcus aureus | Q34141095 | ||
| Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children | Q34157657 | ||
| The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges | Q34401421 | ||
| Increased mortality with accessory gene regulator (agr) dysfunction in Staphylococcus aureus among bacteremic patients | Q34737343 | ||
| Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q34783668 | ||
| Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis | Q35030135 | ||
| Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia | Q35879117 | ||
| High vancomycin MIC and complicated methicillin-susceptible Staphylococcus aureus bacteremia | Q35980091 | ||
| Investigation of reduced susceptibility to glycopeptides among methicillin-resistant Staphylococcus aureus isolates from patients in Ireland and evaluation of agar screening methods for detection of heterogeneously glycopeptide-intermediate S. aureu | Q36098762 | ||
| Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin | Q36870858 | ||
| Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection | Q37114426 | ||
| The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. | Q37981103 | ||
| Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period | Q41066970 | ||
| Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method | Q42169334 | ||
| A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides | Q42912582 | ||
| Predictors of persistent methicillin-resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin | Q43143854 | ||
| Is high vancomycin minimum inhibitory concentration a good marker to predict the outcome of methicillin-resistant Staphylococcus aureus bacteremia? | Q43208168 | ||
| The impact of confounder selection criteria on effect estimation | Q43670469 | ||
| Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact | Q44132698 | ||
| Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy | Q44959085 | ||
| Persistent bacteremia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein | Q45023859 | ||
| High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity | Q45302930 | ||
| Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin | Q46100665 | ||
| Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections | Q46431265 | ||
| Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q46826194 | ||
| Antibiotic Choice May Not Explain Poorer Outcomes in Patients With Staphylococcus aureus Bacteremia and High Vancomycin Minimum Inhibitory Concentrations | Q57763234 | ||
| Predicting who dies depends on how severity is measured: implications for evaluating patient outcomes | Q71777737 | ||
| Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05 | Q80595494 | ||
| Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004-2009 | Q83215855 | ||
| Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets | Q83770914 | ||
| Vancomycin minimum inhibitory concentration and outcome in patients with Staphylococcus aureus bacteremia: pearl or pellet? | Q84531634 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Staphylococcus aureus | Q188121 |
| vancomycin | Q424027 | ||
| P304 | page(s) | 5164-5170 | |
| P577 | publication date | 2012-07-23 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Effect of reduced vancomycin susceptibility on clinical and economic outcomes in Staphylococcus aureus bacteremia | |
| P478 | volume | 56 |
| Q38286351 | Antimicrobial resistance: impact on clinical and economic outcomes and the need for new antimicrobials. |
| Q33703519 | Comparison of commercial antimicrobial susceptibility test methods for testing of Staphylococcus aureus and Enterococci against vancomycin, daptomycin, and linezolid |
| Q58762088 | Effects of pharmacist intervention in Vancomycin treatment for patients with bacteremia due to Methicillin-resistant Staphylococcus aureus |
| Q40655950 | Effects of vancomycin versus nafcillin in enhancing killing of methicillin-susceptible Staphylococcus aureus causing bacteremia by human cathelicidin LL-37. |
| Q38843037 | Impact of Time to Appropriate Therapy on Mortality in Patients with Vancomycin-Intermediate Staphylococcus aureus Infection. |
| Q41825567 | In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure |
| Q36856946 | Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections? |
| Q41340004 | Managing skin and soft-tissue infection and nosocomial pneumonia caused by MRSA: a 2014 follow-up survey |
| Q47236751 | Protein-inspired antibiotics active against vancomycin- and daptomycin-resistant bacteria. |
| Q37203845 | Vancomycin MIC Does Not Predict 90-Day Mortality, Readmission, or Recurrence in a Prospective Cohort of Adults with Staphylococcus aureus Bacteremia |
Search more.